COMP <GO>
AMRX vs JNJ // RETURN ON INVESTED CAPITAL (ROIC)
Amneal Pharmaceuticals Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: AMRX 4
— JNJ 8
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: JNJ
LAST: $21.35 (+0.99%) • MKT CAP: $7.44B
roic
14.10%
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
roic
25.50%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AMRX VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AMRX | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 36.90% | 67.90% | -31.00 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 14.10% | 25.50% | -11.40 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 21.4x | 18.5x | +2.90 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 3.63% | 2.97% | +0.66 | AMRX | /fcf-yield <GO> |
| Operating Margin | 13.10% | 34.70% | -21.60 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 2.40% | 28.50% | -26.10 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 8.00% | 6.00% | +2.00 | AMRX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.83 | 5.59 | -1.76 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 8/9 | +1.00 | AMRX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 65.1 | 62.1 | +3.00 | AMRX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 1.08 | 0.00 | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 96.0x | 23.0x | +73.00 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.44B | $662.49B | -$655.06B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AMRX REV | JNJ REV | AMRX GROSS % | JNJ GROSS % | AMRX FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.02B | $94.19B | 36.9% | 67.9% | $269.9M | $19.70B |
| FY 2024 | $2.79B | $88.82B | 36.5% | 69.1% | $243.2M | $19.84B |
| FY 2023 | $2.39B | $85.16B | — | — | $237.9M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AMRX // BETA 1.08
JNJ // BETA 1.08